Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice

Journal of Virology

Volumn 86, Issue 3, 2012, Pages 1500-1513

  Giles, Brendan M ^a   Bissel, Stephanie J ^b   Craigo, Jodi K ^a,b   DeAlmeida, Dilhari R ^a   Wiley, Clayton A ^b   Tumpey, Terrence M ^c   Rossa, Ted M ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; VIRUS LIKE PARTICLE VACCINE;

2009 H1N1 INFLUENZA; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BRONCHUS; CONTROLLED STUDY; CROSS REACTION; FEMALE; GENE EXPRESSION; GENETIC ENGINEERING; HISTOPATHOLOGY; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; LOWER RESPIRATORY TRACT INFECTION; LUNG INFECTION; MORBIDITY; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; VIRUS GENE; VIRUS IMMUNITY; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS STRAIN;

AGING; ANIMALS; ANTIBODIES, VIRAL; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PNEUMONIA, VIRAL;

ANIMALIA; MURINAE; MUS; ORTHOMYXOVIRIDAE; SUIDAE;

EID: 84857099922     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06034-11     Document Type: Article

References (78)

1. Ahmed R, Oldstone MBA, Palese P. 2007. Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nat. Immunol. 8:1188-1193.
2. Askonas B, McMichael A, Webster R. 1982. The immune response to influenza viruses and the problem of protection against infection, p 159-188. In Beare AS (ed), Bascin and applied influenza research. CRC Press, Boca Raton, FL.
3. Basler CF, Aguilar PV. 2008. Progress in identifying virulence determinants of the 1918 H1N1 and the Southeast Asian H5N1 influenza A viruses. Antiviral Res. 79:166 -178.
4. Bautista E, et al. 2010. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N. Engl. J. Med. 362:1708-1719.
5. Bissel SJ, et al. 29 June 2011. Acute murineH5N1influenzaAencephalitis. Brain Pathol. [Epub ahead of print.] doi:10.1111/j.1750-3639.2011.00514.x.
6. Bissel SJ, et al. 2002. Macrophages relate presynaptic and postsynaptic damage in simian immunodeficiency virus encephalitis. Am. J. Pathol. 160:927-941.
7. Boraschi D, et al. 2010. Ageing and immunity: addressing immune senescence to ensure healthy ageing. Vaccine 28:3627-3631.
8. Bright RA, et al. 2008. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 3:e1501.
9. Bright RA, et al. 2007. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25:3871-3878.
10. Bright RA, et al. 2005. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366:1175-1181.
11. Bright RA, Ross TM, Subbarao K, Robinson HL, Katz JM. 2003. Impact of glycosylation on the immunogenicity of a DNA-based influenza H5HA vaccine. Virology 308:270-278.
12. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295:891-894.
13. Chan M. 11 June 2009, posting date. World now at the start of 2009 influenza pandemic. World Health Organization, Geneva, Switzerland. http://who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html.
14. Chong Y, et al. 2005. CD27+ (memory) B cell decrease and apoptosisresistant CD27- (naive) B cell increase in aged humans: implications for age-related peripheral B cell developmental disturbances. Int. Immunol. 17:383-390.
15. Chowell G, et al. 2009. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N. Engl. J. Med. 361:674-679.
16. Coleclough C, Sealy R, Surman S, Marshall DR, Hurwitz JL. 2005. Respiratory vaccination of mice against influenza virus: dissection of Tand B-cell priming functions. Scand. J. Immunol. 62:73-83.
17. da Silveira SA, et al. 2002. Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity antierythrocyte autoantibody. J. Exp. Med. 195:665-672.
18. de Bruijn IA, et al. 1999. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J. Infect. Dis. 179:31-36.
19. Dogan I, et al. 2009. Multiple layers of B cell memory with different effector functions. Nat. Immunol. 10:1292-1299.
20. Dörner T, Radbruch A. 2007. Antibodies and B cell memory in viral immunity. Immunity 27:384-392.
21. Frasca D, Diaz A, Romero M, Landin AM, Blomberg BB. 2011. Age effects on B cells and humoral immunity in humans. Ageing Res. Rev. 10:330-335.
22. Frasca D, et al. 2010. Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans. Vaccine 28:8077- 8084.
23. Frasca D, et al. 2008. Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells. J. Immunol. 180:5283-5290.
24. Giles BM, Ross TM. 2011. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 29:3043-3054.
25. Gill JR, et al. 2010. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch. Pathol. Lab. Med. 134:235-243.
26. Greenspan NS, Dacek DA, Cooper LJ. 1989. Cooperative binding of two antibodies to independent antigens by an Fc-dependent mechanism. FASEB J. 3:2203-2207.
27. Guarner J, et al. 2006. Histopathologic and immunohistochemical features of fatal influenza virus infection in children during the 2003-2004 season. Clin. Infect. Dis. 43:132-140.
28. Gupta S, et al. 2004. Characterization of naïve, memory and effector CD8+ T cells: effect of age. Exp. Gerontol. 39:545-550.
29. Hancock K, et al. 2009. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 361:1945-1952.
30. Haynes JR, et al. 2009. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 27:530-541.
31. Huang Y, Kong WP, Nabel GJ. 2001. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J. Virol. 75:4947-4951.
32. Itoh Y, et al. 2009. In vitro and in vivo characterization of new swineorigin H1N1 influenza viruses. Nature 460:1021-1025.
33. Johnson NP, Mueller J. 2002. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull. Hist. Med. 76: 105-115.
34. Joo HM, He Y, Sundararajan A, Huan L, Sangster MY. 2010. Quantitative analysis of influenza virus-specific B cell memory generated by different routes of inactivated virus vaccination. Vaccine 28:2186-2194.
35. Kendal AP, Pereira MS, Skehel JJ. 1982.Concepts and procedures for laboratory-based influenza surveillance.U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Atlanta, GA.
36. Krause JC, et al. 2010. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenzaA(H1N1) viruses. J. Virol. 84:3127-3130.
37. Kuiken T, Taubenberger JK. 2008. Pathology of human influenza revisited. Vaccine 26:D59-D66.
38. Mahmood K, et al. 2008. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26:5393-5399.
39. Manicassamy B, et al. 2010. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog. 6:e1000745.
40. Marcelin G, et al. 2010. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner. J. Infect. Dis. 202:1634-1638.
41. Matassov D, Cupo A, Galarza JM. 2007. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol. 20:441-452.
42. Mauad T, et al. 2010. Lung pathology in fatal novel human influenza A (H1N1) infection. Am. J. Resp. Crit. Care Med. 181:72-79.
43. McBurney SP, et al. 2006. Lentivirus-like particles without reverse transcriptase elicit efficient immune responses. Curr. HIV Res. 4:475-484.
44. McBurney SP, Young KR, Ross TM. 2007. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology 358:334-346.
45. Miao H, et al. 2010. Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J. Virol. 84:6687- 6698.
46. Mitchell JA, Green TD, Bright RA, Ross TM. 2003. Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 21:902-914.
47. Mozdzanowska K, Furchner M, Washko G, Mozdzanowski J, Gerhard W. 1997. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J. Virol. 71:4347-4355.
48. Nefkens I, et al. 2007. Hemagglutinin pseudotyped lentiviral particles: characterization of a new method for avian H5N1 influenza serodiagnosis. J. Clin. Virol. 39:27-33.
49. Panda A, et al. 2010. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J. Immunol. 184:2518-2527.
50. Perlmutter RM, Hansburg D, Briles DE, Nicolotti RA, David JM. 1978. Subclass restriction of murine anti-carbohydrate antibodies. J. Immunol. 121:566-572.
51. Perrone LA, Plowden JK, Garcia-Sastre A, Katz JM, Tumpey TM. 2008. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog. 4:e1000115.
52. Pillet S, et al. 2011. Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets. Vaccine 29:6793-6801.
53. Plotkin SA. 2008. Correlates of vaccine-induced immunity. Clin. Infect. Dis. 47:401- 409.
54. Reed L, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. (Lond.) 27:493-497.
55. Ross TM, Xu Y, Bright RA, Robinson HL. 2000. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat. Immunol. 1:127-131.
56. Sasaki S, et al. 2008. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One 3:e2975.
57. Sasaki S, et al. 2007. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J. Virol. 81: 215-228.
58. Shieh W-J, et al. 2010. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am. J. Pathol. 177:166 -175.
59. Skountzou I, et al. 2010. Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus. J. Immunol. 185:1642-1649.
60. Smith KGC, Light A, Nossal GJV, Tarlinton DM. 1997. The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response. EMBO J. 16: 2996-3006.
61. Steckbeck JD, et al. 2006. Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance. J. Med. Primatol. 35: 248-260.
62. Steckbeck JD, et al. 2005. Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strains. J. Virol. 79:12311-12320.
63. Sun S, et al. 2011. Age-related sensitivity and pathological differences in infections by 2009 pandemic influenza A (H1N1) virus. Virol. J. 8:52.
64. Taubenberger JK, Morens DM. 2006. 1918 influenza: the mother of all pandemics. Emerg. Infect. Dis. 12:15-22.
65. Thompson WW, et al. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179 -186.
66. Toapanta F, Ross T. 2009. Impaired immune responses in the lungs of aged mice following influenza infection. Resp. Res. 10:112.
67. Tobita K. 1975. Permanent canine kidney (MDCK) cells for isolation and plaque assay of influenza B viruses. Med. Microbiol. Immunol. 162:23-27.
68. Tobita K, Sugiura A, Enomote C, Furuyama M. 1975. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med. Microbiol. Immunol. 162:9-14.
69. Tumpey TM, et al. 2005. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310:77-80.
70. Wilson DE, Chosewood LC (ed). 2009. Laboratory biosafety level criteria, p 30-59. In Biosafety in microbiological and biomedical laboratories, 5th ed. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA.
71. Wrammert J, et al. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208:181-193.
72. Wu C-Y, et al. 2010. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One 5:e9784.
73. Xu R, et al. 2010. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. doi:10.1126/science. 1186430.
74. Yoshida T, et al. 2010. Memory B and memory plasma cells. Immunol. Rev. 237:117-139.
75. Young KR, Smith JM, Ross TM. 2004. Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle. Virology 327: 262-272.
76. Yu X, et al. 2008. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 455:532-536.
77. Zhang W, et al. 2010. Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus. Protein Cell 1:459-467.
78. Zimmer SM, et al. 2010. Seroprevalence following the second wave of pandemic 2009 H1N1 influenza in Pittsburgh, PA, U.S.A. PLoS One 5:e11601.